Segment Information - Summary of Company's Financial Data for Development and Commercialization of Pharmaceutical Products Segment (Details) - USD ($)	3 Months Ended
	Mar. 31, 2025	Mar. 31, 2024
Segment Reporting Information [Line Items]
Net product sales	$ 3,080,158	$ 1,735,490
Cost of goods sold	41,613	92,529
Eversana profit sharing	4,297,505	3,139,536
Interest income	118,853	46,058
Interest expense (non-cash)	123,288	124,658
Pharmaceutical Products [Member]
Segment Reporting Information [Line Items]
Net product sales	3,080,158	1,735,490
Cost of goods sold	(41,613)	(92,529)
Eversana profit sharing	(2,618,135)	(1,475,261)
Employee expenses	(638,099)	(696,801)
Professional fees	(704,629)	(503,717)
Stock-based compensation	(84,384)	(254,029)
Sales and marketing expenses	(188,668)	(163,797)
Other operating expenses	(106,373)	(50,576)
Interest income	118,853	46,058
Interest expense (non-cash)	(123,288)	(124,658)
Total segment costs loss and net loss	$ (1,306,178)	$ (1,579,820)